Handelsavisen
prelaunch
Companies Healthcare 170900.KS
17
170900.KS KRX Pharmaceuticals

170900.Ks

$37 250,00
Open in Charts → Attach watcher ⌖
KRW
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
359,2B KRW
P/E
EV / Rev
Div yield
1,50 %
Op margin
-2,2 %
ROE
-4,5 %
Net margin
-3,5 %
Debt / equity
0,84
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company is a pharmaceuticals firm that generates revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.

Business. The company is a pharmaceuticals firm that generates revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY8 analysts
8 buy0 hold0 sell
Avg 12m price target61 244,90

Analyst recommendations

8 analysts · consensus Buy
Buy8
Hold0
Sell0
12-month price target
61 244,90
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
8 analysts · indicative
Ownership
not yet wired
Profitability
-4,5 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 170900.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 170900.KS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company is a pharmaceuticals firm that generates revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a debt-to-equity ratio of 0.84, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 1.52, suggesting it can cover its short-term obligations but with limited excess capacity. The company's price-to-book ratio is 0.62, which is below 1, indicating that the market values the company at a discount to its book value. This may reflect concerns about the company's profitability or future growth prospects.

    Profitability metrics show a challenging performance, with a negative return on equity (ROE) of -4.45% and a negative return on assets (ROA) of -2.02%. These figures are below the typical thresholds for industry leaders and suggest that the company is not generating returns that meet the cost of capital. The operating margin is also negative, with an operating loss of 17.4 billion KRW, which is a significant concern for investors. The company's net income is also negative, at -28.6 billion KRW, further highlighting its financial distress.

    The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases the company's exposure to market-specific risks, such as regulatory changes or economic downturns in its primary operating region. The absence of detailed segment or geographic breakdowns in the available data limits the ability to assess the company's exposure to different markets.

    The company's growth trajectory is mixed. While it reported a revenue of 808.78 billion KRW, the operating and net losses suggest that the company is not currently generating sustainable earnings. Analysts have provided a mean price target of 61,244.90 KRW, which is significantly higher than the current market price of 41,500 KRW, indicating some optimism about the company's future performance. However, the company's free cash flow is negative at -48.17 billion KRW, and its capital expenditures are also negative, suggesting that the company is not investing in growth and may be facing liquidity constraints.

    The company's risk profile is elevated, with a liquidity risk due to negative net cash after subtracting total debt. The risk assessment also highlights the potential for dilution, although the current level is assessed as low. The company's negative operating and net income, combined with its high debt load, increases the risk of financial distress and the potential need for further equity or debt financing, which could dilute existing shareholders.

    Recent events, as reflected in the financial data, indicate a period of financial stress for the company. The negative operating and net income, along with the negative free cash flow, suggest that the company is not currently generating sufficient cash to sustain operations or fund growth. The company's capital expenditures are also negative, indicating a lack of investment in new projects or expansion. These factors, combined with the high debt-to-equity ratio, suggest that the company may need to take corrective actions to improve its financial position.

    Key takeaways
    • The company is currently unprofitable, with negative operating and net income, indicating a need for strategic and operational improvements.
    • The company's liquidity position is moderate, with a current ratio of 1.52, but it faces a liquidity risk due to negative net cash after subtracting total debt.
    • The company's capital structure is moderately leveraged, with a debt-to-equity ratio of 0.84, which may increase financial risk.
    • Analysts have a generally positive outlook, with a mean price target significantly higher than the current market price, suggesting potential for recovery.
    • The company's lack of geographic and segment diversification increases its exposure to market-specific risks.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $37 250,00
    Market cap
    $400.22B
    Enterprise value
    $898.43B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    32.3x
    P / B
    0.6x
    P / Tangible book
    0.6x
    Tangible book
    $642.71B
    Net cash
    -$498.21B
    Current ratio
    1.5
    Debt / equity
    0.8
    ROA
    -2.0%
    ROE
    -4.5%
    Cash conversion
    -97.0%
    CapEx / revenue
    -4.4%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution8 analysts
    Strong buy3
    Buy5
    Hold0
    Sell0
    Strong sell0
    12-month price target$61 244,90 · Median $60 000,00
    Low $59 047,62High $64 761,91
    Operating income · consensus40,3B KRW
    Revenue surprise
    −10,0 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$59 047,62
    Mean$61 244,90
    Median$60 000,00
    High$64 761,91
    Spot$37 250,00
    +64.4 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-2,1 %Below median
    Net Margin-3,5 %Below median
    ROE-4,5 %Below median
    Capex / Rev-4,4 %Above median
    D/E0,84Bottom quartile
    Cash Conv-0,97Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • 170900.KS Market data — financials · 2026-05-26
    • Dong-A ST Co Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    170900.KSCanonical
    KRX · KRW

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage